OralDosed ingredientTherapeutic flag Cosmetic cross-reference

Melatonin

CAS 73-31-4

Melatonin (CAS 73-31-4) is a Phase 4 pharmaceutical compound with 10 bioactivity targets and 4,879 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

4,879

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Melatonin

CAS Number

73-31-4

UNII

JL5DK93RCL

InChIKey

DRLFMBDRBRZALE-UHFFFAOYSA-N

ChEMBL ID

CHEMBL45

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

Melatonex

dosed ingredientnatural productoraltherapeutic flag

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL45 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 20 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Ki	489.95520459770114 nM	174	-
-	AC50	27325.287372262774 nM	137	-
-	Potency	33285.17384615384 nM	60	-
-	IC50	12726.491645614034 nM	56	-
-	GI50	92392.43267857144 nM	56	-
-	EC50	1141.1439313333333 nM	45	-
-	Kd	0.15 nM	2	-
-	Kd	9.15e-11	1	-
-	Kd	9.15 l M-1	1	-
5-hydroxytryptamine receptor 2B GPCR	Ki	5.2	-	Homo sapiens
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme	Ki	7.56	-	Homo sapiens
Melatonin receptor type 1A GPCR	EC50	9.4	-	Homo sapiens
Melatonin receptor type 1B GPCR	EC50	9.7	-	Homo sapiens
Nuclear receptor ROR-alpha Nuclear hormone receptor	EC50	9	-	Homo sapiens
Myeloperoxidase Enzyme	IC50	5.52	-	Homo sapiens
Histamine H3 receptor GPCR	Ki	9.3	-	Homo sapiens
Melatonin receptor type 1B GPCR	Ki	9.15	-	Gallus gallus
Cytochrome P450 1B1 Enzyme	Ki	4.85	-	Homo sapiens
Melatonin receptor GPCR	Ki	9.75	-	Gallus gallus
Melatonin receptor type 1C GPCR	EC50	9.91	-	Xenopus laevis

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Intentional self-injury	427	687.935	10022524
Intentional overdose	539	446.473	10022523
Appendicolith	165	351.148	10074458
Somnolence	787	347.523	10041349
Appendicitis	183	236.787	10003011
Pneumonia aspiration	291	203.08	10035669
Gastrooesophageal reflux disease	379	181.097	10017885
Pemphigus	3	166.036	10034280
Synovitis	11	146.666	10042868
Constipation	667	145.468	10010774
Coma	308	140.565	10010071
Cardiogenic shock	184	140.507	10007625
Contraindicated product administered	33	136.309	10078504
Congenital hiatus hernia	43	134.329	10010501
Systemic lupus erythematosus	22	134.022	10042945
Hand deformity	6	132.18	10061194
Desmoplastic small round cell tumour	29	131.53	10064581
Maternal exposure during pregnancy	25	131.237	10071408
Glossodynia	15	124.565	10018388
Treatment failure	43	119.115	10066901
Ascites	251	117.896	10003445
Stress	262	117.607	10042209
Insomnia	576	116.352	10022437
Blood phosphorus increased	85	109.142	10050196
Aplastic anaemia	106	105.926	10002967
Ventricular fibrillation	141	105.258	10047290
Hallucination	264	104.967	10019063
Joint swelling	121	103.508	10023232
Pericarditis	9	103.357	10034484
Arthropathy	59	102.352	10003285
Wound	23	100.456	10052428
Seizure	446	99.371	10039906
Agitation	274	98.395	10001497
Victim of child abuse	35	96.133	10047401
Abdominal distension	309	93.574	10000060
Exposure during pregnancy	22	91.874	10073513
Aggression	172	80.791	10001488
Suicidal ideation	233	80.665	10042458
Rheumatoid arthritis	93	78.929	10039073
Discomfort	39	77.002	10013082
Epidural lipomatosis	32	76.939	10067599
Drug ineffective	944	71.88	10013709
Alopecia	143	70.873	10001760
Hyponatraemia	337	63.217	10021036
Multiple organ dysfunction syndrome	255	60.02	10077361
Myasthenia gravis	62	59.066	10028417
Helicobacter infection	11	58.051	10054263
Cestode infection	18	57.581	10061039
Drug intolerance	166	56.675	10061822
Tremor	346	55.956	10044565

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 3 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
MT 1 receptor MTNR1A	Full agonist	9.100000381469727 pKi	12764576\|9089668\|2991499
MT 2 receptor MTNR1B	Full agonist	9.399999618530273 pKi	12764576\|9089668\|2991499
5-HT 2B receptor HTR2B	Antagonist	5.2 pKi	12750432

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
MELATONIN	6711	SU	MTHSPL
Melatonin	6711	SU	MTHSPL
melatonin	6711	IN	RXNORM
Melatonex	1245031	BN	RXNORM

SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Abdominal discomfort	melatonin	LLT	C0232487
Abdominal discomfort	melatonin	PT	C0232487
Abdominal discomfort	melatonin	PT	C0232487
Abdominal pain	melatonin	LLT	C0000737
Abdominal pain	melatonin	PT	C0000737
Abdominal pain upper	melatonin	LLT	C0232492
Abdominal pain upper	melatonin	PT	C0232492
Abnormal bowel sounds	melatonin	LLT	C0159060
Abnormal dreams	melatonin	LLT	C0234458
Abnormal dreams	melatonin	PT	C0234458
Affect lability	melatonin	PT	C0233472
Aggression	melatonin	LLT	C0001807
Aggression	melatonin	PT	C0001807
Agitation	melatonin	LLT	C0085631
Agitation	melatonin	PT	C0085631
Angina pectoris	melatonin	LLT	C0002962
Angina pectoris	melatonin	PT	C0002962
Angioedema	melatonin	LLT	C0002994
Angioedema	melatonin	PT	C0002994
Angiopathy	melatonin	LLT	C0042373
Angiopathy	melatonin	PT	C0042373
Anxiety	melatonin	LLT	C0003467
Anxiety	melatonin	PT	C0003467
Arthralgia	melatonin	LLT	C0003862
Arthralgia	melatonin	PT	C0003862
Arthritis	melatonin	LLT	C0003864
Arthritis	melatonin	PT	C0003864
Asthenia	melatonin	LLT	C0004093
Asthenia	melatonin	PT	C0004093
Asthenia	melatonin	PT	C0004093
Back pain	melatonin	LLT	C0004604
Back pain	melatonin	PT	C0004604
Blood and lymphatic system disorders	melatonin	-	C0851353
Blood triglycerides increased	melatonin	PT	C0853692
Breast disorder	melatonin	LLT	C0006145
Breast disorder	melatonin	PT	C0006145
Breath odour	melatonin	LLT	C0018520
Breath odour	melatonin	PT	C0018520
Cardiac disorder	melatonin	LLT	C0018799
Cardiac disorder	melatonin	PT	C0018799
Chest pain	melatonin	LLT	C0008031
Chest pain	melatonin	PT	C0008031
Connective tissue disorder	melatonin	LLT	C0009782
Connective tissue disorder	melatonin	PT	C0009782
Depressed mood	melatonin	LLT	C0344315
Depressed mood	melatonin	PT	C0344315
Dermatitis	melatonin	LLT	C0011603
Dermatitis	melatonin	PT	C0011603
Dermatitis	melatonin	PT	C0011603
Disorientation	melatonin	LLT	C0233407
Disorientation	melatonin	PT	C0233407
Disturbance in attention	melatonin	LLT	C0233414
Disturbance in attention	melatonin	PT	C0233414
Disturbance in sexual arousal	melatonin	PT	C0855242
Dizziness	melatonin	LLT	C0012833
Dizziness	melatonin	PT	C0012833
Dizziness	melatonin	PT	C0012833
Dreamy state	melatonin	LLT	C0860514
Dreamy state	melatonin	PT	C0860514
Dry mouth	melatonin	LLT	C0043352
Dry mouth	melatonin	PT	C0043352
Dry skin	melatonin	LLT	C0151908
Dry skin	melatonin	PT	C0151908
Dyspepsia	melatonin	LLT	C0013395
Dyspepsia	melatonin	PT	C0013395
Ear and labyrinth disorders	melatonin	-	C0851354
Eczema	melatonin	LLT	C0013595
Eczema	melatonin	PT	C0013595
Erythema	melatonin	LLT	C0041834
Erythema	melatonin	PT	C0041834
Eye disorder	melatonin	LLT	C0015397
Eye disorder	melatonin	PT	C0015397
Fatigue	melatonin	LLT	C0015672
Fatigue	melatonin	PT	C0015672
Flatulence	melatonin	LLT	C0016204
Flatulence	melatonin	PT	C0016204
Galactorrhoea	melatonin	LLT	C0235660
Galactorrhoea	melatonin	PT	C0235660
Gastric disorder	melatonin	LLT	C0038354
Gastric disorder	melatonin	PT	C0038354

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Melatonin used for in pharmaceutical contexts?

Melatonin (CAS 73-31-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Melatonin?

Melatonin has 4,879 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Intentional self-injury, Intentional overdose, Appendicolith, Somnolence, Appendicitis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Melatonin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Melatonin with EU status "permitted".

What clinical phase is Melatonin in?

Melatonin is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Melatonin?

Melatonin has 20 bioactivity rows in this page query. Rendered target entries include 5-hydroxytryptamine receptor 2B, Ribosyldihydronicotinamide dehydrogenase [quinone], Melatonin receptor type 1A, Melatonin receptor type 1B, Nuclear receptor ROR-alpha.